ARS Pharmaceuticals Kicks Off 2026 with Strong First Quarter Performance
ARS Pharmaceuticals, a commercial biopharmaceutical company focused on developing and commercializing innovative treatments, has made a promising start to 2026. The company's first quarter earnings conference call provided insight into its financial results and commercial highlights for the period.
In the first quarter of 2026, ARS Pharmaceuticals generated $22.7 million in total revenue, with $17.5 million coming from U.S. net product revenue for its flagship treatment, neffy. This represents a significant year-over-year increase in volume and revenue, underscoring the company's growing momentum.
The sales growth seen in the first quarter is particularly notable, given that the initial two months of the year are typically the lowest volume period for epinephrine prescriptions due to health insurance deductible resets. ARS Pharmaceuticals' neffy has largely relied on new prescriptions written in-office, but as the market matures and payer access improves, the company expects to see more consistent and scalable long-term growth.
The company's focus remains on three key areas: access, affordability, and adoption. Addressing barriers such as prior authorization and perceived misperceptions of out-of-pocket costs will be critical in driving further growth this year. ARS Pharmaceuticals ended the first quarter with approximately 90% commercial coverage, including 57% without prior authorization.
In a significant development, Florida has added neffy to its unrestricted formulary effective July 1st, and several other states are progressing towards adding it to their preferred drug lists. The company is optimistic about securing additional formulary additions, particularly following an updated proposal submitted to CVS Health's Caremark, Aetna, and Anthem.
ARS Pharmaceuticals' commitment to making neffy more affordable for patients will also play a crucial role in driving growth this year. A new initiative launched by the company aims to address misperceptions of high out-of-pocket costs, further improving healthcare provider willingness to prescribe neffy.
